These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38946478)

  • 41. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
    Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
    Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study.
    Oka Y; Matsumoto J; Takeda T; Iwata N; Niimura T; Ozaki AF; Bekku K; Hamano H; Araki M; Ishizawa K; Zamami Y; Ariyoshi N
    Int J Clin Pharm; 2024 Jun; 46(3):745-750. PubMed ID: 38632203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database.
    Yang C; Zhao W; Chen H; Yao Y; Zhang J
    Sci Rep; 2024 Jul; 14(1):16202. PubMed ID: 39003359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.
    Liu W; Lin S; Zhu X; Yin L; Liu Q; Lei S; Feng B
    Front Immunol; 2024; 15():1433075. PubMed ID: 39290710
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
    Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
    Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
    Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
    World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
    Sato K; Mano T; Iwata A; Toda T
    Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system.
    Li Z; Zou W; Yuan J; Zhong Y; Fu Z
    Expert Opin Drug Saf; 2024 Jun; 23(6):763-770. PubMed ID: 37515501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring the Relationship Between Atorvastatin and Memory Loss: A Comprehensive Analysis Integrating Real-World Pharmacovigilance and Mendelian Randomization.
    Chen K; Chen Y; Huang H
    Drugs R D; 2024 Jun; 24(2):317-329. PubMed ID: 38963511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.
    Peyton CC; Chipollini J; Azizi M; Kamat AM; Gilbert SM; Spiess PE
    World J Urol; 2019 Oct; 37(10):2017-2029. PubMed ID: 30535583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
    Crijnen J; De Reijke TM
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis.
    Dai MF; Wang X; Xin WX; Kong SS; Xu WB; Ding HY; Fang L
    Expert Rev Anticancer Ther; 2024 Jul; 24(7):613-622. PubMed ID: 38761169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.